📊 GILD Key Takeaways
Is Gilead Sciences, Inc.. (GILD) a Good Investment?
Gilead demonstrates exceptional profitability (29% net margin, 85.2% gross margin) and outstanding cash generation ($2.4B free cash flow, 34.9% FCF margin), providing strong financial stability. However, flat net income growth (0% YoY) despite 2.4% revenue growth and modest earnings expansion suggest the company faces growth headwinds or margin pressures that warrant monitoring.
Gilead shows strong fundamental profitability and cash generation, with $10.02B of operating cash flow and $9.46B of free cash flow supporting resilience. Balance sheet liquidity and interest coverage are solid, but revenue growth is modest and net income was flat year over year, which suggests growth quality is steady rather than accelerating. The very large EPS jump relative to flat net income also raises the possibility of non-operating or one-time effects, so the core earnings trend should be watched closely.
Gilead Sciences, Inc.. Key Strengths (GILD)
- Exceptional profitability with 29% net margin and 85.2% gross margin demonstrates pricing power and operational leverage
- Outstanding free cash flow generation of $2.4B (34.9% FCF margin) provides capital for R&D, debt reduction, and shareholder returns
- Strong balance sheet with manageable leverage (0.94x Debt/Equity) and excellent interest coverage (10.2x) ensures financial stability
- Solid liquidity position with current ratio of 1.97x and $7.6B cash reserves
- Strong operating profitability and cash generation, with 34.0% operating margin and 32.1% free cash flow margin
- Healthy financial flexibility, including $7.56B in cash, 1.55x current ratio, and 39.5x interest coverage
- High returns on capital base, with 37.5% ROE and 14.4% ROA indicating efficient earnings generation
GILD Stock Risks: Gilead Sciences, Inc.. Investment Risks
- Flat net income growth (0% YoY) despite 2.4% revenue growth indicates margin compression or operational challenges
- Modest revenue growth of 2.4% suggests potential pipeline weakness or market maturation in core products
- Elevated debt load of $22.2B limits financial flexibility and creates refinancing risk in higher rate environment
- Low returns on equity (8.6%) and assets (3.6%) suggest suboptimal capital efficiency relative to large asset base
- Top-line growth remains limited at 2.4% year over year, while net income was flat, pointing to slower fundamental growth
- Leverage is meaningful, with $24.94B in long-term debt and debt/equity of 1.10x
- Reported EPS growth far exceeded net income growth, which may indicate earnings quality distortion from non-recurring items or capital structure effects
Key Metrics to Watch
- Revenue growth trajectory and new product pipeline contribution
- Operating and net margin sustainability amid potential competitive pressures
- Free cash flow allocation strategy (debt reduction vs. R&D investment vs. shareholder returns)
- Debt refinancing activity and interest rate exposure
- Product-level revenue growth and total revenue acceleration
- Net income growth and free cash flow consistency
Gilead Sciences, Inc.. (GILD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 34.9% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
GILD Profit Margin, ROE & Profitability Analysis
GILD vs Healthcare Sector: How Gilead Sciences, Inc.. Compares
How Gilead Sciences, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Gilead Sciences, Inc.. Stock Overvalued? GILD Valuation Analysis 2026
Based on fundamental analysis, Gilead Sciences, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Gilead Sciences, Inc.. Balance Sheet: GILD Debt, Cash & Liquidity
GILD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Gilead Sciences, Inc..'s revenue has shown modest growth of 8% over the 5-year period. The most recent EPS of $4.50 reflects profitable operations.
GILD Revenue Growth, EPS Growth & YoY Performance
GILD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $6.7B | $1.3B | $1.04 |
| Q3 2025 | $7.5B | $1.3B | $1.00 |
| Q2 2025 | $7.0B | $1.6B | $1.29 |
| Q1 2025 | $6.7B | $1.3B | $1.04 |
| Q3 2024 | $7.1B | $1.3B | $1.00 |
| Q2 2024 | $6.6B | $1.0B | $0.83 |
| Q1 2024 | $6.4B | $1.0B | $0.80 |
| Q3 2023 | $7.0B | $1.8B | $1.42 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Gilead Sciences, Inc.. Dividends, Buybacks & Capital Allocation
GILD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Gilead Sciences, Inc.. (CIK: 0000882095)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GILD
What is the AI rating for GILD?
Gilead Sciences, Inc.. (GILD) has a Combined AI Grade of A from Claude (A) and ChatGPT (B) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GILD's key strengths?
Claude: Exceptional profitability with 29% net margin and 85.2% gross margin demonstrates pricing power and operational leverage. Outstanding free cash flow generation of $2.4B (34.9% FCF margin) provides capital for R&D, debt reduction, and shareholder returns. ChatGPT: Strong operating profitability and cash generation, with 34.0% operating margin and 32.1% free cash flow margin. Healthy financial flexibility, including $7.56B in cash, 1.55x current ratio, and 39.5x interest coverage.
What are the risks of investing in GILD?
Claude: Flat net income growth (0% YoY) despite 2.4% revenue growth indicates margin compression or operational challenges. Modest revenue growth of 2.4% suggests potential pipeline weakness or market maturation in core products. ChatGPT: Top-line growth remains limited at 2.4% year over year, while net income was flat, pointing to slower fundamental growth. Leverage is meaningful, with $24.94B in long-term debt and debt/equity of 1.10x.
What is GILD's revenue and growth?
Gilead Sciences, Inc.. reported revenue of $7.0B.
Does GILD pay dividends?
Gilead Sciences, Inc.. pays dividends, with $1,040.0M distributed to shareholders in the trailing twelve months.
Where can I find GILD SEC filings?
Official SEC filings for Gilead Sciences, Inc.. (CIK: 0000882095) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GILD's EPS?
Gilead Sciences, Inc.. has a diluted EPS of $1.61.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is GILD's fundamental grade?
Based on our AI fundamental analysis in June 2026, Gilead Sciences, Inc.. has a A grade with 78% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is GILD stock overvalued or undervalued?
Valuation metrics for GILD: ROE of 8.6% (sector avg: 15%), net margin of 29.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is GILD's AI grade for 2026?
Our dual AI analysis gives Gilead Sciences, Inc.. a combined A grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is GILD's free cash flow?
Gilead Sciences, Inc..'s operating cash flow is $2.5B, with capital expenditures of $117.0M. FCF margin is 34.9%.
How does GILD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 29.0% (avg: 12%), ROE 8.6% (avg: 15%), current ratio 1.97 (avg: 2).